The table below shows NOVAVAX INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$139.51M
$70.44M
$239.24M
$666.65M
$84.51M
$415.48M
Cost of revenue
$30.70M
$21.50M
$15.32M
$14.12M
$60.62M
$46.24M
Gross profit
-
-
-
-
-
-
R&D
$95.47M
$98.27M
$79.23M
$88.94M
$87.16M
$106.95M
NVAX annual revenue (10-K history)
NOVAVAX INC reported annual revenue of $1.12B for fiscal year 2025. That is up 64.7% from $682.16M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $15.35M (FY 2016) to $1.12B. Figures come from the company's audited annual reports as filed with the SEC.
